The U.S. Department of Veterans Affairs (VA) has launched a clinical trial to evaluate whether GLP-1 medications can help treat alcohol use disorder in veterans. Multiple military outlets report that the study will test semaglutide-based drugs marketed as Ozempic and Wegovy. The trial is designed to examine the potential effectiveness of these medications for alcohol use disorder within the veteran population, using the VA’s research framework for new or repurposed treatments.
All three sources agree on the core elements: the VA is conducting a trial, the medications involved are Ozempic and Wegovy, and the target condition is alcohol use disorder among veterans. The reports do not provide additional shared details such as the study’s enrollment size, locations, dosing schedule, or primary outcome measures. The initiative reflects an effort to investigate whether medications approved for other indications may offer benefits for substance-use treatment in a clinical setting.
